Association Between Urinary Biomarkers and CKD in Extremely Low Gestational Age Neonates
Sangeeta R Hingorani,Robert H Schmicker,Brian Halloran,Patrick Brophy,Patrick J Heagerty,Sandra Juul,Stuart L Goldstein,David Askenazi,PENUT Investigators,Billy Thomas,Nahed Elhassan,Sarah Mulkey,Philip Dydynski,Vivek K Vijayamadhavan,Neil Mulrooney,Bradley Yoder,Jordan S Kase,Jennifer Check,Semsa Gogcu,Erin Osterholm,Sara Ramel,Catherine Bendel,Cheryl Gale,Thomas George,Michael Georgieff,Tate Gisslen,Sixto Guiang 3rd,Anne Hall,Dana Johnson,Katie Pfister,Heather Podgorski,Kari Roberts,Erin Stepka,Melissa Engel,Heidi Kamrath,Johannah Scheurer,Angela Hanson,Katherine Satrom,Susan Pfister,Ann Simones,Erin Plummer,Elizabeth Zorn,Camilia R Martin,Deirdre O'Reilly,Nicolas Porta,Catalina Bazacliu,Jonathan Williams,Dhanashree Rajderkar,Frances Northington,Raul Chavez Valdez,Sandra Beauman,Patel Saurabhkumar,Magaly Diaz-Barbosa,Arturo Serize,Jorge Jordan,Debbie Ott,Ariana Franco Mora,Pamela Hedrick,Vicki Flynn,Amy Silvia,Bailey Clopp,John B Feltner,Isabella Esposito,Stephanie Hauge,Samantha Nikirk,Andrea Purnell,Emilie Loy,Natalie Sikes,Melanie Mason,Jana McConnell,Tiffany Brown,Henry Harrison,Denise Pearson,Tammy Drake,Jocelyn Wright,Debra Walden,Annette Guy,Jennifer Nason,Morgan Talbot,Kristen Lee,Sarah Penny,Terri Boles,Melanie Drummond,Katy Kohlleppel,Charmaine Kathen,Brian Kaletka,Shania Gonzales,Cathy Worwa,Molly Fisher,Tyler Richter,Alexander Ginder,Brixen Reich,Carrie Rau,Manndi Loertscher,Laura Bledsoe,Kandace McGrath,Kimberlee Weaver Lewis,Jill Burnett,Susan Schaefer,Karie Bird,Clare Giblin,Rita Daly,Kristi Lanier,Kelly Warden,Jenna Wassenaar,Jensina Ericksen,Bridget Davern,Mary Pat Osborne,Brittany Gregorich,Neha Talele,Evelyn Obregon,Tiglath Ziyeh,Molly Clarke,Rachel E Wegner,Palak Patel,Molly Schau,Annamarie Russow,Kelly Curry,Susan Sinnamon,Lisa Barnhart,Charlamaine Parkinson,Mary Hanson,Elizabeth Kuan,Conra Backstrom Lacy,Edshelee M Galvis,Susana Bombino,Denise Martinez,Suzi Bell,Corrie Long,Cathy Longa,Michael Westerveld,Stacy McConkey,Anne Hay,Niranjana Natarajan,Shari Gaudette,Sarah Cobb,Gregory Sharp,Elizabeth Schumacher,Leslie Schuschke,Charlotte Frey,Mario Fierro,Lois Gilmore,Pamela Lundequam,Ronald Hoekstra,Anastasia Ketko,Nina Perdue,Sean Cunningham,Kelly Stout,Becky Hall,Galina Morshedzadeh,Betsy Ostrander,Sarah Winter,Lauren Cox,Matthew A Rainaldi,Sarah Hensley,Melissa Morris,Dia Roberts,Melissa Tuttle,Christopher Boys,Solveig Hultgren,Elizabeth I Pierpont,Nancy Fahim,Tom George,Kelly E King,Katherine Bataglia,Cathy Neis,Mark Bergeron,Cristina Miller,Cara Accomando,Jennifer Anne Gavin,Elizabeth Maczek,Susan Marakovitz,Aimee Knorr,Vincent C Smith,Jane E Stewart,Marie Weissbourd,Raye-Ann deRegnier,Nana Matoba,Shelly C Heaton,Erika M Cascio,Janet Brady,Suman Ghosh,Jessica Ditto,Mary Leppert,Jean Lowe,Janell Fuller,Tara DuPont,Robin Ohls,Pamela Kloska,Saurabh Patel,Lauren Carbonell,Anna Maria Patino-Fernandez,Carmen de Lerma,Kelly McDonough,Maiana De Cortada,Lacy Chavis,Jane Shannon
DOI: https://doi.org/10.1053/j.ajkd.2023.09.008
Abstract:Rationale & objective: Children born before 28 weeks' gestation are at increased risk of chronic kidney disease (CKD). Urine biomarkers may shed light on mechanistic pathways and improve the ability to forecast CKD. We evaluated whether urinary biomarkers in neonates of low gestational age (GA) are associated with a reduced estimated glomerular filtration rate (eGFR) over time. Study design: A cohort study of neonates with an exploratory case-control study of a subset of the cohort. Setting & participants: 327 neonates born at 24-27 weeks' gestation with 2-year eGFR data from the PENUT (Preterm Erythropoietin Neuroprotection Trial) and the REPaIReD (Recombinant Erythropoietin for Prevention of Infant Renal Disease) study. Exposures: 11 urinary biomarkers measured at 27, 30, and 34 weeks' postmenstrual age for the primary cohort study and 10 additional biomarkers for the exploratory case-control study. Outcomes: eGFR<90mL/min/1.73m2 at 2 years corrected for GA. Analytical approach: Linear mixed models to assess differences in biomarker values between neonates in whom CKD did and did not develop, accounting for multiple comparisons using Bonferroni-Holm correction in the cohort study only. Cohort analyses were adjusted for sex, GA, and body mass index. Cases were matched to controls on these variables in the case-control study. Results: After adjusting for weeks of GA, urinary levels of α-glutathione-S-transferase (log difference, 0.27; 95% CI, 0.12-0.43), albumin (log difference, 0.13; 95% CI, 0.02-0.25), and cystatin C (log difference, 0.19; 95% CI, 0.04-0.34) were higher in those in whom CKD developed than in those in whom it did not. Urinary albumin and cystatin C levels did not remain significantly different after Bonferroni-Holm correction. In the exploratory case-control analysis, there were no differences in any biomarkers between cases and controls. Limitations: Early deaths and a high number of subjects without eGFR at 2 years corrected for GA. Conclusions: Measurement of urinary biomarkers may assist in monitoring neonates who are at risk for CKD. Additional studies are needed to confirm these findings. Funding: Grants from government (National Institutes of Health). Trial registration: Registered at ClinicalTrials.gov with study number NCT01378273. Plain-language summary: Approximately 15 million neonates worldwide are born prematurely, and 2 million are born before 28 weeks' gestation. Many of these children go on to experience chronic kidney disease. Urine biomarkers may allow for early recognition of those at risk for the development of kidney disease. In this study of more than 300 children born before 28 weeks' gestational age, we found higher mean urinary levels of α-glutathione-S-transferase at 27, 30, and 34 weeks in children whose estimated glomerular filtration rate was<90mL/min/1.73m2 at 2 years compared with children whose estimated glomerular filtration rate was>90mL/min/1.73m2 at 2 years. Measurement of urinary biomarkers may assist in monitoring neonates who are at risk for chronic kidney disease. Additional studies are needed to confirm our findings.